Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval

Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials for HS-10509, a Category 1 drug developed in-house for the treatment of schizophrenia. The specific indication for the drug will be determined through the clinical trial process.- Flcube.com